Open AccessTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
Author(s) -
Alcibey Alvarado-González,
Isabel Arce
Publication year - 2015
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr2305w
Subject(s) - medicine , tiotropium bromide , bronchodilator , copd , asthma , lama , bronchodilator agents , pulmonary disease , pulmonary function testing , intensive care medicine , anesthesia , pharmacology , lung function , lung
Inhaled bronchodilators are the mainstay of pharmacological treatment for stable chronic obstructive pulmonary disease (COPD), including β2-agonists and muscarinic antagonists. Tiotropium bromide, a long-acting antimuscarinic bronchodilator (LAMA), is a treatment choice for moderate-to-severe COPD; its efficacy and safety have been demonstrated in recent trials. Studies also point to a beneficial role of tiotropium in the treatment of difficult-to-control asthma and a potential function in the asthma-COPD overlap syndrome (ACOS). Combination of different bronchodilator molecules and addition of inhaled corticosteroids are viable therapeutic alternatives. A condensation of the latest trials and the rationale behind these therapies will be presented in this article.